Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Madrigal Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor ...

Robert E. Waltermire, Senior Vice President and Chief Pharma Development Officer at Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company with a market capitalization of $6.39 ...

Rebecca Taub, President of Research and Development and Chief Medical (TASE:PMCN) Officer at Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), recently sold 1,689 shares of the company's common stock. The ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a ...

Citi analyst David Lebowitz maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) yesterday and set a price target of ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma skyrocketed by 281%. In 2024, Fierce Biotech reported 192 ...

Novo Nordisk, for its part, is expected to jump from 10th place to sixth this year, according to Evaluate Pharma’s consensus forecasts. Nevertheless, it’s Roche that’s been tipped to stand ...

Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker. Merck's cancer drug Keytruda ...

Veeda Group has unveiled a new logo and brand identity—Veeda Lifesciences—reflecting ... with reputable sponsors, including leading global pharma companies.

President-elect Trump’s plan to enact heavy tariffs on certain imports could affect the prices and availability of pharmaceutical drugs in the U.S. Trump has floated 25 percent tariffs on ...